We also found no change in the amount of c-Myc in response to ARV825 in either cell line, which is typically considered the most common downstream target of BET (24), suggesting that ARV825 might exert anticancer effects through a different mechanism in CCA than in other cancer types. This evidence concerns the gene MYC and cholangiocarcinoma.